Compound ID | 1787
Class: Antisense oligonucleotide
Spectrum of activity: | Gram-negative |
Details of activity: | Active against E.coli. Inhibits the fatty acid pathway by silencing the AcpP gene |
Description: | Synthetic compound. The challenge of uptake and internalisation of an antisense oligonucleotide is addressed by a new porin translocation technology. |
Institute where first reported: | Pedanius Therapeutics |
Year first mentioned: | 2019 |
Highest developmental phase: | Preclinical |
Development status: | Active (as of 2022) |
External links: | |
Citation: | https://pedaniustherapeutics.com/pipeline |
Patent: | WO2020109792A1 |